There is great medical need for estrogens with favorable pharmacological profiles that support desirable activities for menopausal women, such as metabolic and vascular protection, but that lack stimulatory activities on the breast and uterus. We report the development of structurally novel estrogens that preferentially activate a subset of estrogen receptor (ER) signaling pathways and result in favorable target tissue–selective activity. Through a process of structural alteration of estrogenic ligands that was designed to preserve their essential chemical and physical features but greatly reduced their binding affinity for ERs, we obtained “pathway preferential estrogens” (PaPEs), which interacted with ERs to activate the extranuclear-initiated signaling pathway preferentially over the nuclear-initiated pathway. PaPEs elicited a pattern of gene regulation and cellular and biological processes that did not stimulate reproductive and mammary tissues or breast cancer cells. However, in ovariectomized mice, PaPEs triggered beneficial responses both in metabolic tissues (adipose tissue and liver) that reduced body weight gain and fat accumulation and in the vasculature that accelerated repair of endothelial damage. This process of designed ligand structure alteration represents a novel approach to develop ligands that shift the balance in ER-mediated extranuclear and nuclear pathways to obtain tissue-selective, non-nuclear PaPEs, which may be beneficial for postmenopausal hormone replacement. The approach may also have broad applicability for other members of the nuclear hormone receptor superfamily. PMID: 27221711
Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues
By email@example.com on May 31, 2016 in Extra-nuclear Initiated Estrogen Receptor Signaling, Genomics of Estrogen Receptor Signaling, Metabolism, Systems Biology
- Non-Nuclear Estrogen Receptor Activation Improves Hepatic Steatosis in Female Mice.
- Estrogen receptor-α and aryl hydrocarbon receptor involvement in the actions of botanical estrogens in target cells.
- ERα-XPO1 crosstalk controls tamoxifen sensitivity in tumors by altering ERK5 cellular localization
- Estrogen and Microbiota Crosstalk: Should We Pay Attention?
- Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer